Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthetic apelin fatty acid conjugates with improved half-life

A technology of conjugates and fatty acids, which is applied in the preparation of the composition and in the field of treating cardiovascular diseases, and can solve problems such as sensitivity to protease activity

Inactive Publication Date: 2017-11-28
NOVARTIS AG
View PDF87 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, such bioconjugates may still be susceptible to protease activity, or may no longer be as active as their non-conjugated analogs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic apelin fatty acid conjugates with improved half-life
  • Synthetic apelin fatty acid conjugates with improved half-life
  • Synthetic apelin fatty acid conjugates with improved half-life

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0054] In embodiment 1, the invention thus provides a conjugate or a pharmaceutically acceptable salt thereof comprising:

[0055] a. APJ agonist peptides having the following formula (I):

[0056] Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F (I); or an amide or ester thereof, or a peptide substantially equivalent thereto; wherein the two cysteine ​​amino acids marked with "*" are in their side chains Disulfide bonds are formed between the thiol functional groups of

[0057] b. Fatty acids selected from:

[0058]

[0059] wherein the fatty acid is covalently linked to the N-terminus of the peptide via one of its carboxylic acid functional groups, optionally via a polyethylene glycol linker.

Embodiment approach 1A

[0060] In Embodiment 1A, the invention relates to a conjugate, or a pharmaceutically acceptable salt thereof, comprising:

[0061] a. APJ agonist peptides having the following formula (I):

[0062] Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F (I); where the two cysteine ​​amino acids marked with "*" form a disulfide bond between the thiol functional groups in their side chains; and

[0063] b. Fatty acids selected from:

[0064]

[0065] wherein the fatty acid is covalently linked to the N-terminus of the peptide via one of its carboxylic acid functional groups, optionally via a polyethylene glycol linker.

[0066] The fatty acids described in Embodiment 1 or 1A have been described in US Provisional Application No. 62 / 082327 (PAT056274-US-PSP2).

[0067] Any polyethylene glycol linker group is optional. The linker is polymeric in nature, being a polyethylene glycol moiety containing two reactive groups / functional groups, one of which is reactive with the polypeptide of formula I and ...

Embodiment 1

[0399] Example 1: Fatty Acid-Linker #1-Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F(C 6 -C 12 disulfide bridge)

[0400]

[0401] step 1:

[0402] To a solution of Intermediate 1b (300 mg, 0.096 mmol) in THF (100 mL) was added fatty acid-linker construct #_1 (960 mg, 0.575 mmol) in THF (35 mL) and water (15 mL). The reaction mixture was stirred at room temperature. When complete, the reaction was concentrated under partial vacuum and carried on to the next step as crude, assuming quantitative yield. (Product MW: 4681.870)

[0403]

[0404] Step 2: Deprotection:

[0405] To a solution of TFA (4.75 mL), TIPS (0.125 mL) and water (0.125 mL) was added DTT (296 mg, 1.920 mmol). Then, the premixed mixture was added to the compound of Step 1 (449 mg, 0.096 mmol), and stirred at room temperature. When complete, the reaction was concentrated under partial vacuum. The residue was treated with cold diethyl ether to give a cloudy reaction mixture which was allowed to stand at room...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a conjugate, or a pharmaceutically acceptable salt thereof, comprising a synthetic polypeptide of Formula I: Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F (I) or a amide or ester thereof; and a fatty acid selected from: wherein said fatty acid is covalently linked to the N-terminus of the peptide via one of its carboxylic acid functionality, optionally via a polyethylene glycol linker; and wherein the two cysteine amino acids labeled with * form a disulfide bond between the thiol functionalities of their side chain. The conjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the conjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Description

Field of invention: [0001] The present invention relates to compositions comprising a semi-synthetic biomolecule which is a bioconjugate of an APJ agonist polypeptide and a fatty acid moiety. Specifically, compared to their corresponding naked polypeptides and / or compared to previously described Apelin bioconjugates, the bioconjugates of the present invention both retain APJ agonistic activity and exhibit resistance to the action of the peptide via peptidases. Greater resistance to proteolytic degradation. The invention also relates to methods of preparing said compositions and methods of using said compositions as pharmaceutically active agents for the treatment of cardiovascular diseases. Background of the invention: [0002] In the Western world, the incidence of heart failure accounts for about 1 / 100 of those over 65 years of age. The most common pathology is chronic insufficiency of myocardial contractility and thus cardiac output (ie, the effective volume of blood ej...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47A61K47/54A61K47/60A61K38/17A61P9/04A61P9/12A61P9/00A61P9/10A61P9/06A61P3/10A61P3/04A61P25/00
CPCC07K14/47A61K38/00A61K45/06A61K47/60A61K47/542A61K38/12A61P13/00A61P13/02A61P17/02A61P21/02A61P25/00A61P3/04A61P43/00A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P9/14A61P3/10C07K7/64A61K47/64A61K51/0402
Inventor A·坎特A·R·尤塞拉F·泽克里
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com